10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

7Buy

10Hold

1Sell

Consensus RatingNeutral# Analysts18Avg. Consensus PT$56Upside to Avg. PT-13.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Dan Brennan	PT Raise	Hold	$47→$70
Oct 13, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$40→$70
Oct 12, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$60→$100
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$52→$110
Sep 29, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$40→$90
Sep 28, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$47→$80
Sep 28, 2026	Argus Research	John Eade	Initiate	Buy	$110
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Neutral	$20→$68
Sep 1, 2026	RBC Capital	Dan Leonard	Initiate	Sector Perform	$70
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40

Analyst Ratings News

PRO
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $40 to $70.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $60 to $100.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $52 to $110.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.

Benzinga Newsdesk

10x Genomics Inc

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

PRO
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

PRO
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

People Also Watch

People Also Watch

10x Genomics Inc

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

PROMorgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

PROCanaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

PROBarclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

PROLeerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PROPiper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

PRO
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

PRO
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80